Study Group: CellCept Prescribers(?)
Council Members in this Study Group: 52
Request a survey with this Study Group
Leading Experts in this Study Group
Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Dipti Doshi, MD, is a board certified Rheumatologist at Health Care Partners Medical group, California. Dr. Doshi is also board certified in Internal Medicine. Her special interests are in rheumatoid arthritis, lupus, pain-related to scleroderma, fibromyalgia, and osteoarthritis. Dr. Doshi is interested...
Avram Goldberg, MD,FACRAssistant Professor
Albert Einstein College of Medicine
Avram Goldberg, MD, FACR, is an Attending Physician at North Shore University Hospital and an Assistant Professor at the Albert Einstein College of Medicine, New York. He is part of the Division of Rheumatology where he is responsible for treatment of autoimmune and musculoskeletal diseases including...
Vincent Ho, MD, FRCPCProfessor of Dermatology
The University of British Columbia
Vincent Ho, MD, FRCPC, is a Professor of Dermatology at University of British Columbia in Canada. He has expertise in dermatologic therapeutics including general dermatology such as psoriasis, eczema, and acne as well as cosmetic dermatology including use of Botox, dermal fillers, and skin care products,...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
This article addresses government policy, taxation, insurance, and socialization implications on future patient access to physician care.
Vimpat was developed to have applicability to other disease processes including neuropathic pain. The limited indication approved for Vimpat suggests the data for other potential uses was not very robust (that had been my observation based on the neuropathic pain studies). Although UCB may be developing...
Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...
IVIg (intraveonus immunoglobulin) reduces disability and reduces risk of relapse in patients with CIDP (chronic inflammatory demyelinating polyradiculoneuropathy).
ESA's under pressure because of FDA black box warning. Ferumoxytol has safety and efficacy data to support NDA. Ease of use will immediately give it access to HD market and will grow pre ESRD CKD market, as is appropriate.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Academic Institution*
- Non-Academic Community Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Physician - Division Head
- Director
- Physician - Department Chair
- Assistant Professor
- Professor
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms